UNR844 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia
Trial Timeline
Jun 30, 2021 → Oct 14, 2022
NCT ID
NCT04806503About UNR844 + Placebo
UNR844 + Placebo is a phase 2 stage product being developed by Novartis for Presbyopia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04806503. Target conditions include Presbyopia.
What happened to similar drugs?
1 of 6 similar drugs in Presbyopia were approved
Approved (1) Terminated (1) Active (5)
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04806503 | Phase 2 | Terminated |
Competing Products
14 competing products in Presbyopia